Blink Health LLC, a provider of consumer price discounts for prescription drugs, said it has terminated its relationship with Express Scripts Holding Co., a pharmacy-benefit manager that helped arrange the new price break for Lilly’s insulin.
NYS Entity Status
NYS Filing Date
JUNE 03, 2014
NYS DOS ID#
NYS Entity Type
DOMESTIC LIMITED LIABILITY COMPANY
2014 - DECATUR ST HOLDINGS LLC
AROUND THE WEB
- Blink Health Ends Pact With Express Scripts for Lilly Insulin Price Discounts
Tuesday Jun 13, 2017
- Trailer Bought To Hold Victims Of Terrorism Now Holds Victims Of Heroin Overdoses
By Laura Northrup - Monday Jun 26, 2017
In 2012, St. Louis County in Missouri used a grant from the Department of Homeland Security to buy a refrigerated trailer that can hold more than 20 human bodies. The trailer was intended for use after a terrorist attack or natural disaster, and the county is fortunate that the money spent to buy it was wasted. Until now, when the …
- Young Socialites Conjure the Ghost of Leonard Bernstein at the Dakota
By BEN WIDDICOMBE - Saturday Jun 24, 2017
When Larry Milstein, 22, and his sister Toby, 24, are not hobnobbing on the young socialite circuit, they hold séances in their family’s apartment.
- Growing custom menswear brand Indochino debuts downtown
By Daniel Geiger - Thursday Jul 6, 2017
The custom menswear brand Indochino on Thursday opened its second store in the city, at 25 Broad St. in the Financial District.The store and showroom is the latest example of a company founded...
To view the full story, click the title link.
- That Decisive Moment: Chilling Fervor: This Week’s 8 Best Classical Music Moments on YouTube
Friday Jul 21, 2017
Political messages from the pianist Igor Levit and the conductor Daniel Barenboim were among the highlights.
- FDA advisers review data on potential 1st US gene therapy
By LINDA A. JOHNSON, AP Medical Writer - Wednesday Jul 12, 2017
Cancer experts who advise government regulators are reviewing what could be the first gene therapy approved in the U.S.The Food and Drug Administration panel is holding a hearing Wednesday to discuss the treatment developed by the University of Pennsylvania and Novartis Corp. The drugmaker is seeking approval to use the one-time treatment for children and young adults with advanced leukemia.